Invasive candidosis in pediatric patients  by Roilides, Emmanuel et al.
ORIGINAL ARTICLE
Invasive candidosis in pediatric patients
Emmanuel Roilides1, Isaac Kadiltsoglou 1, Dimitrios Zahides2 and Evangelia Bibashi2
13rd Department of Pediatrics, University of Thessaloniki, and 2Department of Microbiology at
Hippokration Hospital, Thessaloniki, Greece
Objective: To analyze invasive Candida infections in pediatric patients and to examine the outcome of disease.
Methods: An observational prospective study was carried out of microbiologically documented cases of invasive
candidosis in neonates, infants and children at Hippokration Hospital from December 1993 to July 1995.
Results: Thirty-nine cases of invasive candidosis (mainly candidemia and candiduria) occurred in 38 patients aged 3
days to 14 years, 21 (54%) having occurred in patients aged <1 month. The incidence was 10.1/1000 admissions in the
two neonatal departments versus 1.1/1000 for all other pediatric departments, including oncology (p<0.01). The most
frequent causes of hospitalization were premature birth or perinatal problems and surgery. Thirty-five strains of Candida
albicans, 10 of C. parapsilosis and eight of other or unidentified species were isolated. Non-C. albicans isolates, especially
C. parapsilosis and C. glabrata, exhibited higher minimal inhibitory concentrations of azoles as compared with C.
albicans. Thirteen patients (34%), all candidemic, died within 0--40 days. Untreated patients more frequently had positive
cultures up to time of death (p<0.0001) and died (p=O.0006).
Conclusions: Invasive candidosis is frequent in pediatric patients, especially premature neonates, and is associated
with increased mortality. With early diagnosis and initiation of therapy the outcome is favorable.
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Invasive mycoses have increased substantially during
recent years and have emerged as frequent nosocomial
infections in immunocomprornised patients [1-4].
Fungi comprise the fourth most common cause of
nosocomial infections today [5], and Candida spp. are
the most frequent isolates in these cases. Patients with
various immune defects (such as those associated with
neoplasia or premature birth), those receiving broad-
spectrum antibiotics and those bearing indwelling
catheters appear to be the most susceptible to invasive
candidosis. A mortality of 35-70% has been associated
with this infectious complication in adults [5].
Invasive candidosis has also become an important
problem in pediatrics, but to our knowledge, except for
specific patient groups [6-8], epidemiologic studies
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have been limited [9-11] and data on antifungal drug
susceptibility, therapy and outcome among children are
scarce. The purpose of this study was to analyze the
spectrum of invasive infections caused by Candida spp.
in pediatric patients and the susceptibility of the isolates
to antifungal drugs, and to examine the outcome of
disease in these patients.
PATIENTS AND METHODS
We conducted an observational prospective study of
invasive infections due to Candida spp. that occurred
between December 1993 and July 1995 in neonates,
infants and children admitted to various wards of
Hippokration General Hospital, Thessaloniki, Greece,
to assess their incidence, the role of possible risk factors
and the impact of antifungal therapy. Only micro-
biologically documented cases were analyzed. Two
of the authors followed these patients closely during
the entire course of invasive candidosis and advised
primary physicians regarding the management of them;
however, the primary physicians made the ultimate
decisions about clinical management.
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RESULTS
Table 1 Characteristics of neonates, infants and children
with invasive candidosis
'In parenthesis, percentage of patients with the characteristic.
bVesicoureteral reflux, ureteropelvic junction obstruction, renal
transplantation.
CFour neonates had umbilical catheters, two neonates had Hickman
catheters and one neonate had a peritoneal catheter.
Thirty-nine cases of invasive candidosis were encoun-
tered in 38 patients of ages 3 days to 14 years during
the 20-month period between December 1993 and
July 1995. A premature infant suffered from candidemia
twice at 2 and 4 months of age. Twenty-one cases
(54%) were documented in the neonatal age group «1
month) and 18 in infancy and childhood. The demo-
graphics of all patients and particularly of neonates, the
causes ofhospitalization and the possible risk factors for
invasive candidosis are shown in Table 1. The incidence
of candidosis was 10.1/1000 admissions in the two
neonatal departments, as compared with 1.1/1000 for
all the other pediatric departments, including oncology
(p<O.Ol). All episodes of invasive candidosis occurred
:2:3 days after patients' admission; thus they were
classified as nosocomial infections. Fourteen of 38
patients with invasive candidosis (37%) had indwelling
venous or arterial catheters (11), a peritoneal catheter
(2) or a bladder catheter (2).
14/7
7 (33)C
5 (24)
19 (90)
15 (71)
21 (100)
31.5 weeks,
26-40 weeks
15 (71)'
9 (43)
Age <1 month
21
18 days, 3-30 days
1000 g, 500-1990 g
2 (5)
1 (3)
25 (66)
20 (53)
14 (37)
7 (18)
28 (74)
5 (13)
2 (5)
3 (8)
All patients
38
1 month,
3 days to 14 years
22/16
<38 weeks
<30 weeks
Birth weight
(median, range)
Cause of hospitalization
Prematurity or
perinatal disease
Surgery
Neoplasia
Otherb
Risk factors
Previous broad-spectrum
antibiotic use
Premature birth
Catheters (umbilical,
Hickman, peritoneal,
Foley)
Necrotizing enterocolitis
Neoplasia-associated
neutropenia
Renal transplantation
Number
Age (median, range)
Sex (boysl girls)
Gestational age
(median, range)
Characteristic
Cultures sent to the microbiology laboratory from
all neonatal and pediatric departments were monitored
for growth of Candida in conventional microbiological
media. Blood and other appropriate cultures were taken
when fever or other signs of infection were manifested.
No specific frequency for drawing cultures was preset,
but the average frequency was every 2-4 days as long
as symptoms and signs of infection persisted. After
diagnosis, another culture was drawn before the in-
stitution of antifungal therapy and, with the same
frequency, thereafter until negative cultures were
obtained or the patient died. Positive cultures from
non-sterile sites (i.e. stools) were considered only if
they were associated with cultures of sterile sites (i.e.
blood) positive with the same Candida species.
The data that were recorded consisted of: (1)
clinical characteristics, such as age, sex and cause of
hospitalization of the patients; (2) microbiological
characteristics, such as pathogen(s) isolated, dates and
time ofcultures to become positive, number ofpositive
cultures, susceptibility to antifungal agents, antifungals
administered, duration of therapy and outcome of
infection; and (3) possible risk factors, such as presence
of indwelling catheters, broad-spectrum antibiotic use
and necrotizing enterocolitis in premature neonates. In
the neonates, additional data such as gestational age,
weight at birth, preceding history of infectious or non-
infectious problems and length of stay in the neonatal
intensive care unit before infection were also recorded.
The following definitions were used: candidemia
was defmed as positive blood culture(s) drawn from
either an intravascular catheter or a peripheral vein.
Urinary tract infection was defined as positive culture(s)
of urine obtained by suprapubic aspiration or bladder
catheterization.
Candida albicans was identified by the germ tube
test. The panels API 20C Aux or ID32 (bioMerieux,
69280 Marcy-I'Etoile, France) were used for identi-
fication of other yeasts. For susceptibility testing of
isolates to amphotericin B, flucytosine, fluconazole and
itraconazole, the macrobroth dilution method M-27P
of determination of minimal inhibitory concentrations
(MIC) standardized by National Committee for
Clinical Laboratory Standards (NCCLS) was used [12].
Minimal lethal concentrations (MLC) were determined
by subculturing the contents of tubes without visible
growth on Sabouraud agar containing 2% dextrose.
To estimate rates of infection per 1000 admissions,
all admissions that occurred during this period at each
pediatric department of the hospital were calculated.
For statistical evaluation of differences in the
proportions, chi-squared test and Fischer's exact test
were used. The two-tailed p values are given for each
evaluation.
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'One patient was lost to follow-up, and culture results of one
patient could not be retrieved.
Table 2 Candida spp. and sites of patients from which they
were isolated
Table 3 Microbiological features of invasive candidosis in
neonates, infants and children
'c. albicam from synovial, cerebrospinal and peritoneal fluid (2),
skin site of catheter and stools (2); C. parapsilosis from peritoneal
flUId, stools (2) and eye secretions; C. glabrata from tip of
peritoneal catheter; C. pseudotropicalis from peritoneal fluid.
bIn parenthesis, percentage of cases due to corresponding species.
candidosis. In addition, seven isolates came from eye
secretions, stools, the hub of a venous catheter and the
tip of a peritoneal catheter. All cultures yielded single
species. A Candida isolate was obtained from a single
site in 30 episodes and from multiple (2-3) sites in nine
episodes. Other microbiological features of invasive
candidosis, such as number and duration of positive
cultures as well as the time required for cultures to
become positive, are summarized in Table 3. For
example, the majority of patients had only one culture
positive for Candida. In addition, the patients with
multiple positive cultures had two to four positive
cultures drawn during a median period of8.5 days. The
mean time for cultures to become positive was 2.6 days.
The MICs of amphotericin B, flucytosine, fluco-
nazole and itraconazole were determined by the
NCCLS method for 28 isolates of C. albicans, seven
isolates of C. parapsilosis, and six isolates of other
Candida species, and are shown in Table 4. All C.
albicans isolates tested showed low MICs of the four
antifungals, whereas C. parapsilosis and certain of the
other Candida species showed higher MICs. In addition,
MLCs of the four antifungals for the same isolates were
determined (Table 4). Amphotericin B was lethal for
all C. albicans isolates tested, with MLC ::;;2 I-lg/mL,
whereas fluconazole and itraconazole were only in-
hibitory. C. parapsilosis and the other Candida species
exhibited more variable MLCs.
In three patients there were seven serial isolates of
C. albicans (two patients) and C. parapsilosis (one
patient) derived from the same or different biological
materials with a time difference from 1 week to almost
4 months. There was no more than a two-fold change
of MIC in the subsequent isolates.
Twenty-eight courses of antifungal chemotherapy
were administered to 26 patients (68%) for 27 episodes
of invasive candidosis. They consisted of conventional
amphotericin B or liposomal amphotericin B alone in
nine and five cases, respectively, or in combination with
flucytosine in 10 cases and with fluconazole in three
cases. One patient received fluconazole alone. The
median daily dose of conventional amphotericin B was
0.8 mg/kg (range 0.25-1 mg/kg) and of liposomal
amphotericin B 2.5 mg/kg (range 0.5-3.5 mg/kg).
The median duration of therapy with conventional
amphotericin B was 10 days (range 4-25 days) as com-
pared to 13 days (2-63 days) for liposomal ampho-
tericin B. The median total amount of conventional
or liposomal amphotericin B administered was 9.1
mg/kg (range 1.25-220 mg/kg). Twelve patients (32%)
received no therapy.
Two umbilical catheters, one peritoneal catheter
and one bladder catheter were removed in four of 14
patients bearing an indwelling catheter (29%) when
22
15
3 (2-4)
Finding
8.5 days (2-40 days)
2 days (1-10 days)
Duration of positive cultures in patients
with 2:2 positive cultures, median (range)
Time to become positive, median (range)
Feature
Number of positive cultures in patients
with 2:2 positive cultures, median (range)
Number of patients with positive cultures'
1 culture
2:2 cultures
Blood Urine Other' Number of cases
Species (N=30) (N=10) (N=13) (N=39)
C. albicans 19 9 7 26 (67)"
C. parapsilosis 5 1 4 6 (15)
C. lusitaniae 2 2 (5)
C. glabrata 2 2 (5)
C. tropicalis 1 1 (3)
C. pseudotropicalis 1 (3)
Undetermined 1 (3)
The infections that were documented were mainly
but not exclusively candidemia and candiduria (Table
2). No major clusters of invasive candidosis were
observed in the various departments during the period.
Seven neonates suffered from multiple-site Candida in-
fections that included candidemia in all seven, urinary
tract infection in four, meningitis in one, peritonitis
in one and multifocal osteoarthritis in one. In one
neonate, candidemia was combined with enterococcal
bacteremia. One to three episodes of microbiologically
documented bacteremia preceded invasive candidosis
in eight neonates. Eleven additional neonates were
receiving antimicrobial agents for presumed bacterial
sepsis prior to diagnosis of invasive candidosis.
The species and sources of 53 Candida isolates as
well as the number of infections in which they were
involved are shown in Table 2. Forty-six isolates came
from normally sterile fluids such as blood, urine,
peritoneal fluid, cerebrospinal fluid and synovial fluid
of 38 patients suffering from 39 episodes of invasive
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Table 4 Minimal inhibitory concentrations (MIC) and minimal lethal concentrations (MLC) of amphotericin E, flu cytosine,
fluconazole and itraconazole in I-!g/mL for Candida spp. isolated
MIC MLC
Drug/Candida species 50%' 90% Range 50% 90% Range
Amphotericin B
C. albicans (28)b 0.25 0.5 (0.125-0.5) 0.5 1 (0.125-2)
C. paraps/losis (7) 0.25 0.5 (0.125-0.5) 1 4 (0.25-4)
Other species (6)' 0.125 0.25 (0.125-0.25) 0.5 0.5 (0.5-2)
Flucytosine
C. albicans (28) 0.25 1 (0.125-4) 1 64 (0.25->64)
C. paraps/losis (7) 0.25 0.5 (0.125-0.5) 2 16 (0.25-16)
Other species (6)' 0.125 4 (0.125-4) 1 2 (0.25-64)
Fluconazole
C. alb/cans (28) 0.5 2 (0.25-4) >64 >64 (64->64)
C. parapsilos/s (7) 4 16 (1-16) 16 64 (4-64)
Other species (6)' 4 16 (1-64) >64 >64 (16->64)
Itraconazole
C. albicans (28) :0;0.06 0.125 (:0;0.06-2) >16 >16 (16->16)
C. parapsilos/s (7) 0.25 2 (0.125-2) 1 8 (0.25-8)
Other species (6)' 0.5 2 (0.125-8) >16 >16 (2->16)
'Percentage of tested isolates inhibited by the stated concentration.
b In parenthesis, number of isolates tested.
c C. lusitan/ae, two isolates; C. glabrata, two isolates; C. trop/calls, one isolate; C. pseudotropicalls, one isolate.
invasive candidosis was diagnosed. One neonate with
an umbilical catheter did not receive antifungal therapy
or have the catheter removed, and died after 2 days.
Among the remaining 13 patients who received anti-
fungal therapy, three of four (75%) who had their
catheters removed recovered from their infections, as
compared with eight of nine (89%) who retained their
catheters.
Thirteen patients (34%), all with candidemia, died
within 0-40 days after microbiological documentation
of invasive candidosis. Eleven of 26 patients aged <3
months (42%) died, as compared to only two of 12
patients aged 23 months (17%) (p >0.05). Three of
these patients died within 1 day after culture result
notification, and prior to beginning antifungal therapy,
while one died 10 days after beginning therapy, with
multiple non-infectious problems. Nine of 12 (75%)
untreated patients, as compared to none of 26 (0%)
treated patients, had one to four positive cultures
and no negative cultures prior to death (p<O.OOOI).
Similarly, nine of 12 (75%) untreated patients, as
compared to four of 26 (15%) treated patients, died
(p = 0.0006). Even after excluding three patients who
died on the same day that invasive candidosis was
diagnosed, the proportion ofpatients who died without
therapy (6/9, 67%) is significantly higher than the
proportion of patients who died despite appropriate
therapy for 2 2 days (4/26, 15%; p=0.007).
DISCUSSION
Invasive mycoses have emerged as frequent nosocomial
infections, predominantly in hospital departments
with immunodeficient patients, including neonates
[1,4,6-9,13]. The most frequent cause of invasive
mycoses still comprises species of Candida. To our
knowledge, this is the first observational prospective
study of invasive candidosis including drug suscepti-
bility of isolated fungi reported in a pediatric popu-
lation. A high incidence of candidosis was found
particularly in neonates as compared to other pediatric
patients. This difference may have been exaggerated by
the pattern of multiple admissions to the oncology
department per patient. However, even if we calculate
the rates of infections by patient rather than by
admission numbers, the difference between the neo-
natal and the non-neonatal departments continues to
be significant (data not shown).
Recent data from the USA demonstrated that
the overall frequency of nosocomial candidemia, the
predominant invasive infection due to Candida, in the
1980s, increased by 219-487% in teaching hospitals
and by 75-370% in other institutions [14]. In our
university hospital, four cases of invasive candidosis
were reported in one of the two neonatal departments
between January 1992 and December 1993, all due
to C. albicans (two cases per year) [15]. In the same
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department with approximately the same number of
patients, we found 13 cases of invasive candidosis
during a period of 20 months (7.8 cases per year).
Nosocomial candidemia accounts for 8-10% of all
hospital-acquired bloodstream infections and generally
occurs at a rate of 0.5-1 case per 1000 patient
admissions. At least one third of these patients die from
invasive candidosis [14]. In our study, 34% of the
patients with invasive candidosis died, with a tendency
for lesser mortality (17%) among infants and children
~3 months of age. It has been reported that invasive
candidosis-associated mortality is significantly lower in
pediatric patients than in adults [9]. This concurs with
our finding, although the majority of our patients
also had other serious problems and the mortality
attributable to candidosis was difficult to determine
accurately.
In our study, the most prominent possible risk
factors were prior use of broad-spectrum antibiotics
followed by premature birth and the presence of intra-
vascular and other catheters. Similar risk factors were
recently reported in pediatric patients by MacDonald
etal.[11].
A favorable outcome of invasive candidosis was
found to be associated with institution of appropriate
antifungal therapy. However, 12 patients did not receive
therapy, four because they died before the culture result
was known and eight because therapy was not con-
sidered necessary by their primary physicians. Three
of the latter patients survived and subsequently had
negative cultures. One patient was a 10-year-old girl
with a kidney transplant who had a urine culture
positive for C. albicans. The other two were full-term
neonates without major risk factors who had one
blood culture positive for C. albicans and C. tropicalis,
respectively. Similar cases of transient fungemia have
been reported by Fraser et al. [10]. They seem to be
due either to lesser pathogenicity of fungi in com-
parison to bacteria in most of the cases or to a greater
tendency of cultures to be contaminated by fungi. The
question of contamination of cultures remains un-
answered. In a large series of nosocomial candidemia
[10], 12% of blood cultures were considered to be
contaminated. In our opinion, antifungal therapy must
be initiated in every child with positive blood culture
after a confirmatory culture is taken.
Amphotericin B is still the 'standard' treatment for
invasive candidosis, alone or combined with flucytosine
or other antifungal agents. No serious adverse effects
were encountered in these patients. Only in one
neonate was amphotericin B replaced by liposomal
amphotericin B because of lack of improvement
(persistent candidemia and multifocal osteoarthritis due
to C. albicans). Lipid formulations of amphotericin B
exhibit reduced tmoClty and high concentrations,
especially in reticuloendothelium-rich organs, and may
offer some help in selected cases of invasive candidosis
in pediatric patients.
Cultures became positive 2 days (median, range
1-10 days) after their inoculation. This delay may
contribute to the increased mortality of invasive
candidosis and supports the notion that physicians need
to have increased suspicion of candidosis before they
have culture results available. Removal of the catheter
did not appear to influence the outcome of candidosis
as an adjunctive measure to antifungal chemotherapy.
This result is different from previously reported findings
[16,17]. Differences in patient populations or the small
number of our patients with catheters may have
contributed to this discordance.
In our study 17 of 52 identified Candida isolates
(33%) were not C. albicans. This proportion of non-C.
albicans Candida isolates is undoubtedly much greater in
comparison to findings of previous studies in Greece
[15,18] and elsewhere [1-3]. The reasons for this
change in epidemiology of Candida are not well under-
stood.
All C. albicans isolates tested were susceptible to
amphotericin B, flucytosine and the newer azoles in
vitro. In contrast, isolates of non-C. albicans species,
in particular C. parapsilosis and the few isolates of
C. glabrata, had more variable susceptibility to azoles,
especially to fluconazole. Similar results have been
published previously for adult patients with invasive
candidosis [19]. In the patients with serial isolates ofthe
same species, there was no tendency towards increased
MIC of antifungal agents at subsequent time points,
as has been shown in patients with AIDS and oro-
pharyngeal candidosis [20]. However, when inter-
preting antifungal drug susceptibility results one has to
keep in mind the difficulties of standardization of
antifungal drug susceptibility testing. In addition, in
other than HIV-infected patients, MIC values have not
been found to be predictive of clinical outcome [19].
In conclusion, invasive candidosis is relatively
frequent in pediatric patients, especially in premature
neonates, and it results in increased mortality in these
patients. Due to its seriousness and difficulties in
diagnosis, it requires continuous clinical suspicion for
early and appropriate management. With early diag-
nosis and initiation of antifungal therapy, its prognosis
can be improved.
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